Lv1
79 积分 2023-10-09 加入
Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
1天前
已完结
Emerging EZH2 Inhibitors and Their Application in Lymphoma
24天前
已完结
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study
24天前
已完结
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial
26天前
已完结
Targeting and engineering biomarkers for prostate cancer therapy
26天前
已完结
Clinical Efficacy and Mechanistic Insights of FDA-Approved HDAC Inhibitors in the Treatment of Lymphoma
1个月前
已完结
Epigenomic heterogeneity as a source of tumour evolution
1个月前
已完结
310 (PB298): Synergistic Anti-Tumor Effects of the Novel HDAC Inhibitor, ABT-301, with Immune Checkpoint Inhibitors in Colorectal Cancer Through Regulation of Immune Response and Anti-Angiogenesis
1个月前
已完结
Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer
1个月前
已完结
Improved prognosis of advanced-stage extranodal NK/T-cell lymphoma: results of the NKEA-Next study
1个月前
已完结
Development and Characterization of Methyl-Anthranilate-Loaded Silver Nanoparticles: A Phytocosmetic Sunscreen Gel for UV Protection
1年前
已采纳
Synthesis of Fe3O4/PDA Nanocomposites for Osteosarcoma Magnetic Resonance Imaging and Photothermal Therapy
1年前
已采纳
皖公网安备34019202002308
